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carcinoma tissue and 40.5 % were non-cancerous tissue. 
Of all cancer lesions, 62.2 % were staged as Ta, 20.1 % 
as T1, 9.3 % as T2, 7.3 % as carcinoma in situ (CIS), and 
1.2 % were unknown. Additional cancer lesions (+6.8 %) 
and CIS lesions (+25 %, p < 0.0001) were detected by 
HALC plus WLC versus WLC alone. In 10.0 % of 
patients, ≥1 additional positive lesion was detected 
with HALC, and 2.2 % of NMIBC patients would have 
been missed with WLC alone. No adverse events were 
observed.
Conclusions The results of this study demonstrate that 
HALC significantly improves the detection of NMIBC 
versus WLC alone in routine clinical practice in Germany. 
While this benefit is statistically significant across all types 
of NMIBC, it seems most relevant in CIS.
Keywords Blue light cystoscopy · Hexaminolevulinate · 
Non-muscle invasive bladder cancer · Observational 
studies · White light cystoscopy
Abstract 
Purpose White light cystoscopy (WLC) is the standard 
procedure for visualising non-muscle invasive bladder can-
cer (NMIBC). However, WLC can fail to detect all cancer-
ous lesions, and outcomes with transurethral resection of 
the bladder differ between institutions, controlled trials, 
and possibly between trials and routine application. This 
noninterventional study assessed the benefit of hexami-
nolevulinate blue light cystoscopy (HALC; Hexvix®, Ipsen 
Pharma GmbH, Germany) plus WLC versus WLC alone in 
routine use.
Methods From May 2013 to April 2014, 403 patients with 
suspected NMIBC were screened from 30 German centres 
to perform an unprecedented detailed assessment of the 
additional detection of cancer lesions with HALC versus 
WLC alone.
Results Among the histological results for 929 biopsy 
samples, 94.3 % were obtained from suspected cancer-
ous lesions under either WLC or HALC: 59.5 % were 
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Introduction
Suspected non-muscle invasive bladder cancer (NMIBC) is 
diagnosed using white light cystoscopy (WLC), followed 
by biopsy [1]; however, WLC can fail to detect 4–41 % of 
papillary Ta and T1 tumours, carcinoma in situ (CIS), dys-
plasia, multifocal growth, and microscopic lesions [2, 3]. 
Visualisation of bladder lesions including residual tumour 
tissue, small tumours, and CIS during transurethral resec-
tion of the bladder (TURB) can be improved with hexami-
nolevulinate blue light cystoscopy (HALC; Hexvix®, Ipsen 
Pharma GmbH, Ettlingen, Germany) [3–6]. Results from 
randomised controlled trials (RCTs) show that WLC plus 
HALC can detect an additional 7–30 % of cancer lesions 
versus WLC alone [6–11].
The quality of TURB and outcomes achieved in clini-
cal studies can vary considerably [6]. Therefore, observa-
tional studies reflecting routine clinical practice are useful 
to assess the benefit of HALC outside of RCTs, since the 
effect of photodynamic diagnosis may differ between these 
settings. Prior observational studies conducted in Italy 
[7], Spain [8] and France [12] showed that in daily clini-
cal practice, HALC can enhance the diagnostic accuracy of 
WLC, resulting in a lower tumour recurrence rate. Detec-
tion rates again varied, potentially reflecting different clini-
cal settings between series.
Because of the observed differences in different coun-
tries, and as changes in EU regulations promote post-
authorisation studies in different countries in Europe [13], 
we conducted a study to assess additional detection of can-
cerous lesions with HALC plus WLC versus WLC alone in 
patients with NMIBC undergoing TURB in routine clini-




During this multicentre, prospective, noninterventional study, 
patients with suspected NMIBC undergoing TURB in daily 
clinical practice were screened from 30 inpatient surgical uro-
logical German centres between May 2013 and April 2014. 
Centres utilising HALC were prospectively selected for 
inclusion. All enrolled patients received HALC and WLC.
The study followed recommendations of the Interna-
tional Epidemiological Association Guidelines for the 
Proper Conduct in Epidemiologic Research, and the Inter-
national Society for Pharmacoepidemiology, Good Phar-
macoepidemiological Practice Guidelines. Applicable local 
independent ethics committee and institutional review 
board approvals were obtained before study initiation.
The primary objective was to assess additional detection 
of NMIBC with HALC compared with WLC alone based 
on lesions in patients undergoing TURB, by analysing the 
detection rate with HALC and WLC versus WLC alone.
Patients
All patients with suspected NMIBC and indication for 
TURB were included. Exclusion criteria included: repeat 
TURB (control TURB) 4–6 weeks after initial TURB, and 
Bacillus Calmette–Guérin (BCG) or mitomycin/intravesi-
cal chemotherapy instillation therapy ≤12 weeks before 
TURB. Inclusion and exclusion criteria followed recom-
mendations in the HALC Summary of Product Character-
istics (SmPC) [14]: contraindications include porphyria and 
hypersensitivity to the active substances/any of the excipi-
ents [14].
Procedure
HALC and WLC were performed during the same surgi-
cal procedure after administration of hexaminolevuli-
nate, according to the SmPC and local clinical practice 
procedure.
Hexaminolevulinate solution (50 ml of 8 mmol/l) should 
be instilled into the bladder via a catheter and retained for 
≥1 h. After emptying the bladder, examination using blue 
light should be started <3 h after instillation. The entire 
bladder was examined and mapped using white light, then 
blue light, and biopsies of mapped lesions were taken [14, 
15].
Lesion detection
In each patient, lesions detected with WLC were num-
bered and their location recorded in a detailed bladder 
map; this was repeated using HALC. It was noted if lesions 
were detected with HALC and/or WLC, and whether 
lesions were confluent or not. Directly following cystos-
copy, findings were recorded in a detailed online system, 
thereby minimising delay between the procedure and 
documentation.
Histology
Histology was performed by the local pathology team of the 
participating centre, and results were added to the online 
patient records at a later stage. Lesions were resected using 
TURB, and biopsies were taken for histological evaluation 
by local pathologists. The biopsy method—cold biopsy or 
resection—was recorded. Lesions were histologically clas-
sified as carcinoma, dysplasia, hyperplasia, healthy tissue, 
inflammation, or unknown.
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Carcinoma lesions were staged according to the tumour, 
nodes, metastasis classification of malignant tumours, and 
graded using the WHO classification (1973 and 2004). 
Individuals with confirmed tumour stage Ta, T1, or CIS 
were assigned to the European Organisation for Research 
and Treatment of Cancer (EORTC) risk scores (i.e. esti-
mated probability of recurrence and progression in patients 
with NMIBC).
Adverse event monitoring
All related adverse events (AEs; serious and non-serious) 
were reported as spontaneous cases.
Monitoring
For each patient, an electronic case report form (eCRF) was 
used; into this eCRF, the investigator entered the collected 
data, the validity of which they were responsible for. Upon 
entry, data were automatically checked for completeness 
and plausibility. Random monitoring to confirm the study 
was being conducted in compliance with the protocol, and 
to verify data were being accurately reported on the eCRF, 
was conducted in approximately 10 % of the participating 
centres.
Statistical analysis
Efficacy analysis was at a patient level and lesion level in 
the per protocol (PP) population, which included all treated 
patients in the intent-to-treat (ITT) population with no 
major protocol deviation, and valid cystoscopy and pathol-
ogy/histology results. The safety analysis was performed 
on the ITT population (i.e. all enrolled patients).
As the study was exploratory, lesions within patients 
were considered quasi-independent (no clustered analysis).
The ratio of true-positive and false-positive fractions 
(rTPF and rFPF) was calculated from measures of sen-
sitivity (=TPF) and specificity (=1-FPF) for HALC and 
WLC, respectively. The TPF was the proportion of lesions 
or patients positively tested during cystoscopy out of all 
lesions or patients, respectively, with histologically con-
firmed carcinoma. The FPF was the proportion of lesions 
or patients positively tested during cystoscopy out of all 
lesions or patients, respectively, with histologically con-
firmed non-carcinoma tissue.
Detection rate was defined as the proportion of lesions 
or patients with lesions detected during the procedure out 
of all lesions or patients, respectively. By definition, detec-
tion rate was 100 % for HALC plus WLC.
The primary efficacy endpoints were rTPF and rFPF 
(with 95 % confidence intervals [CI]) for HALC plus WLC 
versus WLC alone. The McNemar test was used to test 
the null hypothesis of equal sensitivities (rTPF = 1). rTPF 
was estimated (with 95 % CI) to assess the primary objec-
tive by evaluating the impact of HALC plus WLC versus 
WLC alone on the detection of NMIBC. Secondary effi-
cacy endpoints were to assess detection rates with HALC 
plus WLC versus WLC alone for risk groups according to 
EORTC scores. Detection and false-positive rates were also 
compared on a patient level between HALC plus WLC and 
WLC alone. Pearson–Clopper 95 % CIs were calculated for 
these secondary efficacy endpoints.
The planned sample size was 364 patients using the 
assumptions: discordant test results between HALC plus 
WLC versus WLC alone of 12, 80 % power, 5 % alpha 
level, a fraction of the smallest subgroup investigated 
(15 %), and patients with missing histology (13 %).
Post hoc analysis included assessment of additional CIS 
lesion detection with HALC plus WLC versus WLC alone 
and of the number needed to treat for one patient to benefit 
from additional examination with HALC.
Results
Participant flow is summarised in Fig. 1. Overall, 395 
patients received hexaminolevulinate and 379 had valid 
histology from the diagnostic procedure; 97 % of enrolled 
patients completed the procedure.
Baseline patient and disease characteristics for the ITT 
population are summarised in Table 1.
Histology
Of the 941 biopsy samples collected, 929 were histologically 
evaluated. Of these, 876 (94.3 %; 95 % CI 92.6–95.7) were 
from lesions suspicious under WLC and/or HALC, while 53 
(5.7 %; 95 % CI 4.3–7.4) were random samples taken from 
unsuspicious tissue and excluded from analyses. Results 
from histological analysis are summarised in Table 2.
Primary and secondary outcome measures
Of the 403 enrolled patients, 24 (6.0 %) were not submit-
ted to cystoscopy or were without valid cystoscopy results 
(Fig. 1).
Overall, 499 cancerous lesions and 340 non-cancerous 
lesions in the PP population were identified with HALC 
and WLC. HALC identified 6.8 % (34/499) more positive 
lesions than WLC (Fig. 2). The rTPF and rFPF indicated 
that HALC plus WLC detected statistically significantly 
more true-positive and false-positive lesions. From the 839 
suspected lesions, 223 (26.6 %) were false positive under 
WLC and an additional 117 (13.9 %) were false positive 
under HALC.
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Within the PP population, 270 (73.8 %) and 96 (26.2 %) 
NMIBC patients had histologically confirmed cancerous 
lesions and non-cancerous lesions, respectively. Of these 
patients, 234 (86.7 %; 95 % CI 82.0–90.5) had all con-
firmed tumour lesions detected with HALC and WLC, and 
27 (10.0 %; 95 % CI 6.7–14.2) had ≥1 additional positive 
lesion detected with HALC. In the PP population, 2.2 % 
(95 % CI 0.8–4.8) of NMIBC patients would have been 
missed with WLC alone. In these patients, lesions with the 
following tumour stages were documented: two CIS, two 
pTaG1, four pTaG2, and two pT1G3.
On a patient level, and taking into account a study-
design-related 100 % detection rate for HALC and WLC, 
detection rate was 95.4 % (95 % CI 92.7–97.3) for WLC 
alone. The resulting ratio of detection rates of 1.049 
(95 % CI 1.028–1.079; p = 0.0027) indicated that a sta-
tistically significant increase in the number of patients 
with cancerous lesions was observed with WLC plus 
HALC versus WLC alone. The rFPF was 1.157 (95 % 
CI 1.080–1.283; p < 0.0001), indicating that with WLC 
plus HALC versus WLC alone a statistically significantly 
increased number of patients with false-positive lesions 
was observed.
With WLC and HALC, 12 (8.2 %) additional can-
cerous lesions were detected in patients at high risk of 
progression (according to EORTC scores) versus with 
WLC (p < 0.0001). No statistical difference was detected 
between HALC and WLC in those at low (n = 1 [2.1 %]; 
p = 1.0000) and intermediate (n = 8 [4.3 %]; p = 0.0711) 
risk of progression.
Fig. 1  Participant flow chart. ITT intent to treat, PP, per protocol. 
aPatients with available and completed histological data; 8 patients 
included in the PP population received WLC, but did not receive 
HALC, due to either technical problems or organisational issues
Table 1  Baseline patient and disease characteristics (ITT population)
BCG Bacillus Calmette–Guérin, CIS carcinoma in situ, EORTC Euro-
pean organisation for research and Treatment of cancer, NMIBC non-
muscle invasive bladder cancer, SD standard deviation
a Percentages are calculated based on the number of histologically 
evaluated patients with cancerous lesions (n = 282) minus missing 
patients (n = 65), i.e. N = 217
b EORTC is only applicable to patients with cancerous lesions, with 
respective stage Ta, T1, and CIS
Characteristics ITT population (N = 403)
Age (years)
 Mean (SD) 69.9 (10.7)
Sex, n (%)
 Female 114 (28.3)
 Male 289 (71.7)
Current diagnosis is based on n (%)
 Positive urine cytology 34 (8.4)
 Cystoscopy results 356 (88.3)
 Other 65 (16.1)
Suspicion of NMIBC, n (%)
 Primary tumour 275 (68.2)
 Recurrence 126 (31.3)
 Missing 2 (0.5)
Suspicion of CIS, n (%)
 Yes 51 (12.7)
 No 350 (86.8)
 Missing 2 (0.5)
Suspicion of high-grade tumour, n (%)
 Yes 83 (20.6)
 No 318 (78.9)
 Missing 2 (0.5)
Previous BCG instillation, n (%) 20 (5.0)
Mean time between first diagnosis 




 High risk 5 (2.3)
 Intermediate risk 181 (83.4)
 Low risk 31 (14.3)
 Missing 65
EORTC progression riska,b
 High risk 65 (30.0)
 Intermediate risk 102 (47.0)
 Low risk 50 (23.0)
 Missing 65
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In a post hoc analysis, WLC plus HALC identified 9 
(25.0 %) additional CIS lesions in the PP population ver-
sus WLC alone (Fig. 2), with the rTPF indicating that 
HALC detected statistically significantly more CIS lesions 
(p < 0.0001).
Based on the 282 patients in the ITT population 
with histologically confirmed lesions, post hoc analysis 
showed that 16 patients must be examined using HALC 
versus WLC alone to detect one additional patient with 
a cancerous lesion (irrespective of risk of recurrence or 
progression).
No AEs related to treatment with HALC were reported.
Discussion
This study showed that in patients with NMIBC undergo-
ing TURB in routine clinical practice, WLC plus HALC 
detected an additional 34 (6.8 %) cancerous lesions in the 
PP population versus WLC alone (p < 0.0001). While this 
proportion is markedly lower than in a previous observa-
tional study (23.2 %) [7], findings from both are consist-
ent with results from RCTs (range 7–30 %) [6–11]. Large 
ranges in reported results could be due to different docu-
mentation procedures and clinical settings across countries. 
Nevertheless, HALC provides a diagnostic benefit over 
WLC alone for patients with suspected NMIBC, supporting 
its use in daily clinical practice. Indeed, the EAU guide-
lines now recommend use of this imaging modality when 
available for high-risk patients (when cytology is positive 
or when high-risk exophytic tumour is expected) [17]. 
The validity of this approach is confirmed by the current 
study, in which 8.2 % of additional cancerous lesions were 
detected in patients at high risk of progression. Initially 
targeting HALC to high-risk patients seems an appropri-
ate means of introducing the use of this technique within a 
treatment centre. Thus, while HALC may lead to long-term 
benefits across all risk groups compared with WLC, high-
risk patients seem to benefit most [16].
Importantly, significantly more CIS lesions were 
detected with WLC plus HALC versus WLC alone. While 
the effect of HALC was weaker than in a previous observa-
tional study, the rate of CIS was also lower (7.2 % here vs. 
19.4 % in an observational series) [7]. RCTs also reported 
a greater (31.9–70.6 %) detection of additional CIS lesions 
with HALC [3].
In the PP population, 10 % of patients had ≥1 additional 
positive lesion detected with HALC, and WLC would have 
missed 2.2 % of NMIBC patients. Therefore, with WLC plus 
HALC versus WLC alone, more appropriate risk classifica-
tion and optimised treatment management may be possible.
Comparisons with findings from RCTs should be 
viewed with caution. In RCTs, carefully selected patient 
populations managed at specialist centres with potentially 
more experienced surgeons may produce results that are 
not easily transferrable to routine practice at larger or more 
diverse centres. Indeed, TURB is a teaching procedure 
often performed by less experienced surgeons. Likewise, 
local pathology laboratories may yield different results, 
and generally a central pathology laboratory is used in 
RCTs. Hence, results from studies of routine HALC use are 
Table 2  Summary of histology results (PP population)
CIS carcinoma in situ, PUNLMP papillary urothelial neoplasm of low 
malignant potential, WHO world health organisation
a Percentages are calculated based on the number of samples 
obtained from suspicious lesions (n = 839)
b Histology result is either “not selected” or “unknown”
c Only applicable to carcinoma lesions. Percentages are calculated 
based on the number of lesions found to be carcinoma (n = 499)
Parameter statistic/value N (%)
Biopsy samples collected (ITT population), N 941
Histologically evaluated samples (ITT population), N 929
Samples obtained from suspicious lesions, n 839
Histological findingsa
 Carcinoma 499 (59.5)
 Dysplasia 26 (3.1)
 Hyperplasia 29 (3.5)
 Healthy tissue 83 (9.9)
 Inflammation 202 (24.1)
 Unknownb 0 (0.0)
 Missing 0 (0.0)
Tumour stagingc
 Ta 310 (62.1)
 T1 99 (19.8)
 T2 48 (9.6)
 T3 0 (0.0)
 T4 0 (0.0)
 CIS 36 (7.2)
 Unknown 6 (1.2)
Grading WHO 1973c
 G1 130 (26.1)
 G2 205 (41.1)
 G3 108 (21.6)
 Unknown 23 (4.6)
 Not selected 33 (6.6)
Grading WHO 2004c
 PUNLMP 5 (1.0)
 Low grade 251 (50.3)
 High grade 146 (29.3)
 Unknown 62 (12.4)
 Not selected 35 (7.0)
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important to better understand the potential benefits of this 
approach. As outlined above, there is good evidence that 
HALC may offer benefits in terms of detection and out-
come in a range of patients; this benefit may be most sig-
nificant in those with high-risk tumours (as the data from 
this study support), and optimising detection of positive 
lesions will rely on optimising the technique more than via 
patient selection. Furthermore, differences in local histol-
ogy/pathology assessments may contribute to varied results 
between observational studies and clinical trials; conform-
ity in staging and grading is 50–60 % [1]. Importantly, this 
study included sites experienced and inexperienced with 
HALC, reflecting routine practice in Germany.
Enhanced detection during TURB with the use of HALC 
may improve diagnosis of NMIBC in clinical practice, 
improve outcomes, and reduce recurrence rates [4]. The 
finding that HALC detected a significantly higher rate of 
true-positive lesions in patients with high risk of progres-
sion (according to EORTC scores) than WLC may indicate 
that HALC use could improve detection of these patients in 
routine clinical practice, potentially reducing morbidity and 
mortality [8, 11, 17, 18]. While false-positive rates were rel-
atively high with WLC alone and when HALC was added, 
these were within the ranges reported in a previous observa-
tional study that highlighted the wide variation in the rate of 
false positives at different centres (2.6–28.6 % with WLC 
alone and 6.1–39.3 % with the addition of HALC) [8]. 
The present study highlights the importance of thoroughly 
assessing patients in true need of a TURB in advance to 
avoid biopsy in merely inflamed tissue, as a rather large 
fraction of patients showed inflammation only (24.1 %).
Although this study did not assess recurrence rate or 
survival, it is clear that improved visualisation techniques 
allow for more appropriate disease staging and risk classi-
fication and thus guide more appropriate subsequent treat-
ment decisions, as well as allow for better resection of 
the tumour. It is reasonable, therefore, to expect that use 
of HALC would result in longer recurrence-free survival 
compared to WLC alone. The benefits of improved detec-
tion with HALC have already been demonstrated in sev-
eral studies, with significantly reduced recurrence rates at 
1 year. This could potentially reduce the requirement for 
patients to undergo frequent TURBs, which not only have 
a significant negative impact on patient quality of life, but 
also incur a considerable cost [3]. A recent study from 
Sweden modelling the cost consequences of HALC found 
that the technique had a minimal cost impact if introduced 
across all risk groups, and reduced TURBs, cystectomies, 
bed days, and operating room time. Notably, the use of 
HALC translated into cost savings from year 2–5 in this 
model [16].
Despite the large number of patients with primary 
tumours (68.6 %) versus previous studies (43.3 %) [3], 
this study represents a typical population of patients with 
suspected diagnosis of NMIBC within in-patient surgical 
urological institutions in Germany. Similar to other obser-
vational studies, there were no reports of spontaneous AEs 
related to hexaminolevulinate [7, 8].
No subgroup analyses by tumour type were conducted in 
the present study; however, a meta-analysis that did conduct 
such analyses found the benefit of HALC was in patients 
with Ta, T1, CIS, primary and recurrent cancer, and was 
Fig. 2  Histologically confirmed 
lesions detected with HALC 
and WLC (PP Population). 
CIS carcinoma in situ, HALC 
hexaminolevulinate blue light 
cystoscopy, rFPF ratio of 
false-positive fractions, rTPF 
ratio of true-positive fractions, 
WLC white light cystoscopy. By 
definition, the detection rate was 
100 % for HALC plus WLC. 
a2.8 % of cancerous lesions 
were detected by WLC only
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independent of the level of risk [3]. Additional detection rates 
with HALC (compared with WLC alone) ranged from 9.7 to 
40.2 % for Ta tumours, with 239 of 1621 (14.7 %) of addi-
tional Ta tumours only being detected with HALC. For T1 
tumours, detection of additional tumours with HALC ranged 
from 3.6 to 54.5 % of the total T1 tumours detected. In total, 
40 of 372 (10.8 %) of additional T1 tumours were detected 
only by HALC. As in the present study, the benefit of HALC 
was most pronounced in CIS; detection of additional CIS 
lesions ranged from 31.9 to 70.6 % of the total CIS lesions 
detected; and 215 of 527 (40.8 %) of additional CIS lesions 
were detected with HALC alone [3].
Despite meticulous online documentation with detailed 
bladder maps and minimised time delay between proce-
dures and documentation, there remained a number of 
study limitations. Limitations were consistent with other 
observational studies and include: incomplete informa-
tion versus RCTs, and lack of blinding between WLC and 
HALC, which could bias true-positive and false-positive 
observations. However, achieving blinding in routine clini-
cal settings is impossible and also hard to accomplish in 
a diagnostic study. Of note, no tertiary or academic cen-
tres—both of which institutions treat a significant number 
of patients—were included in the present study, and not all 
regions of Germany were equally reflected; either or both 
of these factors may have introduced bias.
Study strengths included observation of a complete and 
typical spectrum of patients with a realistic high number of 
primary tumours and staging distribution, and prevention 
of patient selection bias through recruitment of consecutive 
patients with the required diagnosis.
In conclusion, this study demonstrates that HALC sig-
nificantly improves the detection of NMIBC versus WLC 
alone in daily clinical practice in Germany.
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